GVR Report cover U.S. Cell Therapy Market Size, Share & Trends Report

U.S. Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Autologous, Allogeneic), By Therapeutic Area (Oncology, Dermatology), And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-4-68040-246-5
  • Number of Pages: 80
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2023
  • Industry: Healthcare

U.S. Cell Therapy Market Size & Trends

The U.S. Cell therapy market size was valued at USD 2.66 billion in 2023 and is anticipated to grow at a CAGR of 21.18% from 2024 to 2030. Major factors contributing to this growth include the growing adoption of regenerative medicine, the rising number of clinical trials on cell therapies due to positive therapeutic outcomes, and the introduction of technological advancements in the market.

U.S. Cell Therapy Market size and growth rate, 2024 - 2030

The U.S. cell therapy market accounted for a 56% share of the global cell therapy market in 2023. The increasing number of clinical studies on cellular therapies showcases a growing recognition of their potential across various medical conditions. Pharmaceutical companies are increasingly focusing on exploring and utilizing the therapeutic benefits of cells. Over 2,000 clinical trials were ongoing in the cell and gene therapy field as of January 2023, driven by positive outcomes in early-phase trials. These studies target conditions like cancer, autoimmune disorders, and degenerative diseases, aiming to maximize the therapeutic potential of different cell types, including stem cells and immune cells. Moreover, the advancement of genetic editing technologies like CRISPR-Cas9 enables precise modifications to cells' genetic material thereby driving market growth.

In addition, the growing investments and funding for cell therapies are anticipated to enhance competition in the market. Academic and medical institutions are contributing to improving access to cell therapies. For instance, in October 2022, Cedars-Sinai received a 5-year, USD 8 million grant from California's stem cell agency to establish a new clinic aimed at enhancing access to stem cell and gene therapies. This escalating investment and funding for cell therapies is projected to intensify competition within the market.

Market Concentration & Characteristics

The fragmented landscape of the U.S. cell therapy market is influenced by the presence of numerous companies operating within it. Moreover, companies are investing heavily in clinical trials for these products, and growing research funding from government entities in this sector, is anticipated to expand the industry in the coming years.

U.S. Cell Therapy Market Concentration & Characteristics

The research institutions are introducing cutting-edge cell therapies to significantly improve patient outcomes and escalate customer base. The use of cell therapy in developing advanced treatments provides a promising opportunity to address changing patient needs and advance personalized medicine. For instance, in July 2023, the University of Maryland School of Medicine (UMSOM) researchers developed a novel CAR T-cell therapy that, in preclinical investigations, targeted cancer cells specifically while preserving healthy cells.

Companies in the U.S. cell therapy industry leverage partnership and collaboration strategies to enhance their manufacturing capabilities and expand the geographic reach of their product offerings. Collaborative efforts with various entities, enable companies to access new markets, resources, and opportunities, ultimately strengthening their market presence and competitiveness. for instance, in October 2023, Lupus Therapeutics announced a partnership agreement with Nkarta, Inc. to support the evaluation of Natural Killer (NK) cell therapy in Lupus Nephritis.

The U.S. cell therapy industry is supported by the M&A activities undertaken by various companies. These crucial aspects of strategic management facilitate growth, restructuring, and enhancing competitive positions within the industry. For instance, in November 2023, Selecta Biosciences, Inc. announced a merger with Cartesian Therapeutics, Inc. This merger was accompanied by a $60.25 million private financing. This would result in the introduction of cutting-edge treatments for autoimmune conditions.

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) are increasingly supporting advanced therapies, simplifying approval procedures, enabling allogeneic stem cell therapies for a range of diseases, and nurturing favorable research. The rise in regulatory authorizations within this sector attracted new entrants in the biotechnology sector. For instance, in June 2022, the U.S. FDA granted approval to Bristol Myers Squibb's CAR T Cell Therapy Breyanzi for treating relapsed or refractory Large B-cell Lymphoma.

The rising emphasis on regional expansion by major manufacturers caters to a broad customer base and leverages growth opportunities in various geographical industries. For instance, in October 2023, Bayer AG announced a new cell therapy manufacturing facility in Berkeley, California, USA, with a $250 million investment. This will facilitate the production of materials for clinical trials and an experimental cell therapy for the treatment of Parkinson’s Disease.

Therapy Type Insights

Autologous therapies segment dominated the market with a share of 91% in 2023. The growth is driven by the personalized nature and potential applications of these therapies in treating a wide range of diseases such as cancer, cardiovascular diseases, neurodegenerative diseases, and orthopedic injuries. Moreover, companies are actively developing cell therapies for cardiovascular diseases. For example, BIOCARDIA, INC. is working on CardiAMP Cell Therapy, an autologous cell therapy designed to treat individuals with ischemic heart failure. This trend of increasing these therapies is expected to drive demand over the forecast period.

U.S. Cell Therapy Market share and size, 2023

Allogenic therapies segment is projected to witness growth at the largest CAGR from 2024 to 2030 owing to widespread use in developing innovative treatment approaches. Allogeneic cell therapies offer advantages over autologous cell therapies, such as immediate availability, scalability, and cost-effectiveness. Moreover, significant companies are expanding the production of allogeneic cell therapies. This trend is poised to drive market growth.

Therapeutic Area Insights

The oncology segment held the market with a share of 92% in 2023. The wide applications of cell therapy in the oncology sector are driving the growth. Various cell therapies, including CAR T cell therapies, TCR-based therapies, and allogeneic cord blood-based therapies, are utilized in the treatment of various cancers like blood cancer, melanoma, and multiple myeloma. Additionally, companies increasing their efforts to advance cell therapies for cancer treatment. These features are likely to expand market growth.

The dermatology segment is anticipated to grow at a significant CAGR from 2024 to 2030 owing to advancements in cell therapies for treating skin disorders. Furthermore, the increasing focus of companies on cell therapy for developing dermatological therapeutics is expected to boost the segment growth. For instance, in March 2024, SkinCure Oncology revealed new skin cancer treatment technology at the American Academy of Dermatology Annual Meeting in San Diego. This offers a noninvasive treatment option for non-melanoma skin cancer, providing a targeted and effective approach with high cure rates.

Key U.S. Cell Therapy Company Insights

Increasing development and application of CRISPR-Cas9 and other precise gene-editing tools for creating innovative cell therapy products and rising emphasis on off-the-shelf or allogeneic cell therapies are driving market growth. Moreover, the adoption of M&A activities, collaborations, and the introduction of innovative cell therapies boost market growth.

Key U.S. Cell Therapy Companies:

  • Gilead Sciences, Inc.
  • Selecta Bioscience
  • Bristol-Myers Squibb Company
  • CARGO Therapeutics, Inc.
  • Johnson & Johnson
  • Atara Biotherapeutics, Inc
  • Nkarta, Inc
  • Cellular Biomedicine Group, Inc
  • Vertex Pharmaceuticals Incorporated
  • Aurion Biotech

Recent Developments

  • In January 2024, Cipla revealed a joint venture in the U.S. with Kemwell Biopharma and Manipal Education & Medical Group to globally develop and commercialize innovative cell therapy products.

  • In February 2024, AstraZeneca announced the expansion of its manufacturing presence in the United States to speed up the advancement of next-generation cell therapy discovery and development.

  • In February 2024, Children’s Hospital Los Angeles announced a grant of multi-year $6 million funding by the California Institute for Regenerative Medicine (CIRM) to produce novel stem cell strategies for treating children and teenagers with recurring solid tumors.

U.S. Cell Therapy Market Report Scope

Report Attribute


Revenue Forecast in 2030

USD 10.34 billion

Growth rate

CAGR of 21.18% from 2024 to 2030

Actual data

2018 - 2023

Forecast period

2024 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2024 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Therapy type, therapeutic area

Country scope


Key companies profiled

Gilead Sciences, Inc.; Selecta Bioscience; Bristol-Myers Squibb Company; CARGO Therapeutics, Inc.; Johnson & Johnson; Atara Biotherapeutics, Inc; Nkarta, Inc; Cellular Biomedicine Group, Inc; Vertex Pharmaceuticals Incorporated; Aurion Biotech

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

U.S. Cell Therapy Market Report Segmentation

This report forecasts revenue growth at the country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. Cell therapy market report based on therapy type, and therapeutic area:

  • Therapy Type Outlook (Revenue, USD Million, 2018 - 2030)

    • Allogeneic Therapies

      • Stem Cell Therapies

        • Hematopoietic Stem Cell Therapies

        • Mesenchymal Stem Cell Therapies

      • Non-Stem Cell Therapies

        • Keratinocytes & Fibroblast-based Therapies

        • Others

    • Autologous Therapies

      • T-Cell Therapies

        • CAR T Cell Therapy

        • T Cell Receptor (TCR)-based

      • Others

  • Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

    • Oncology

    • Dermatology

    • Others

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.